Press release
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Analysis| Clinical trials, Insights into the Marketed & Emerging Therapies, Treatment Outlook, Latest Regulatory Approvals, ROA and, Key Companies by DelveInsight
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline
Currently, there are no specific therapeutic cures for Facioscapulohumeral Muscular Dystrophy (FSHD). But in 2010, the standard of care and management of FSHD were discussed, and a census was agreed on at the 171st ENMC International Workshop. The main treatment strategies are divided upon the different aspects of the muscle systems it affects.
"Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular Dystrophy Market.
The Facioscapulohumeral Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Request for Sample PDF Report for Facioscapulohumeral Muscular Dystrophy pipeline Assessment, click here: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Facioscapulohumeral Muscular Dystrophy Pipeline Analysis
The Facioscapulohumeral Muscular Dystrophy report provides insights into:
• The report provides detailed insights about companies that are developing therapies for the treatment of Facioscapulohumeral Muscular Dystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Facioscapulohumeral Muscular Dystrophy Treatment.
• Facioscapulohumeral Muscular Dystrophy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Facioscapulohumeral Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Facioscapulohumeral Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF Report to know more about the recent developments in the Facioscapulohumeral Muscular Dystrophy pipeline, click here - Facioscapulohumeral Muscular Dystrophy clinical trials advancements
Facioscapulohumeral Muscular Dystrophy Therapeutics Landscape
Several key companies are developing therapies for the treatment of Facioscapulohumeral Muscular Dystrophy. The approval of the emerging therapies will be a milestone for patients who have been suffering from Facioscapulohumeral Muscular Dystrophy.
Key companies in the Facioscapulohumeral Muscular Dystrophy (FSHD) Market:
Some of the Facioscapulohumeral Muscular Dystrophy companies working in the market are Fulcrum Therapeutics, Dyne Therapeutics, Facio Therapies, Myocea, Avidity Biosciences, And many more.
To get complete Facioscapulohumeral Muscular Dystrophy pipeline analysis, request for a free sampole report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Facioscapulohumeral Muscular Dystrophy (FSHD) Therapies covered in the report include:
Losmapimod
GBC0905
Targets CK1
And many other
Globally, several prominent pharma companies are actively working on developing therapies for Facioscapulohumeral Muscular Dystrophy. The launch of the emerging therapies is expected to improve the treatment scenario in the coming years.
To get More Detailed Insights Into the Emerging Facioscapulohumeral Muscular Dystrophy Therapies & drugs, click here - https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Current Treatment Patterns
4. Facioscapulohumeral Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment
6. Facioscapulohumeral Muscular Dystrophy Late Stage Products (Phase-III)
7. Facioscapulohumeral Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Facioscapulohumeral Muscular Dystrophy Early Stage Products (Phase-I)
9. Facioscapulohumeral Muscular Dystrophy Pre-clinical Products and Discovery Stage Products
10. Inactive Facioscapulohumeral Muscular Dystrophy Products
11. Dormant Facioscapulohumeral Muscular Dystrophy Products
12. Facioscapulohumeral Muscular Dystrophy Discontinued Products
13. Facioscapulohumeral Muscular Dystrophy Product Profiles
14. Key Companies in the Facioscapulohumeral Muscular Dystrophy Market
15. Key Products in the Facioscapulohumeral Muscular Dystrophy Therapeutics Segment
16. Dormant and Discontinued Facioscapulohumeral Muscular Dystrophy Products
17. Facioscapulohumeral Muscular Dystrophy Unmet Needs
18. Facioscapulohumeral Muscular Dystrophy Future Perspectives
19. Facioscapulohumeral Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Request for Sample PDF Report to know more about the recent developments in the Facioscapulohumeral Muscular Dystrophy pipeline, click here - https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Related Reports:
HPV-Induced Cancers Market:
https://www.delveinsight.com/report-store/hpv-induced-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Ventricular Fibrillation Market:
https://www.delveinsight.com/report-store/ventricular-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Diagnostic Imaging Equipment Market:
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Aortic Aneurysm Stent Grafts Market:
https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Atherectomy Devices Market:
https://www.delveinsight.com/report-store/atherectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Analysis| Clinical trials, Insights into the Marketed & Emerging Therapies, Treatment Outlook, Latest Regulatory Approvals, ROA and, Key Companies by DelveInsight here
News-ID: 2798587 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Facio
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 12+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular Dystrophy Market.
The Facioscapulohumeral…
Facioscapulohumeral Muscular Dystrophy (FSHD) Market is projected to reach USD 4 …
The global Facioscapulohumeral Muscular Dystrophy (FSHD) Market was valued at USD 210 million in 2024 and is projected to reach USD 482 million by 2034, expanding at a CAGR of 8.6% during the forecast period (2025-2034). The market is driven by rising diagnosis rates, advancements in genetic testing, improved clinical awareness among neuromuscular specialists, and accelerating drug development targeting the underlying molecular mechanisms of FSHD.
Download Full PDF Sample Copy of…
Facioscapulohumeral Muscular Dystrophy Market Expected to Evolve Through 2034 Am …
Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most prevalent forms of muscular dystrophy, characterized by progressive skeletal muscle weakness that initially affects the face, shoulders, and upper arms. The condition is genetically linked to abnormal expression of the DUX4 gene, most commonly caused by contraction of the D4Z4 repeat on chromosome 4. FSHD can significantly impact mobility, quality of life, and daily function, though disease progression varies widely among…
Facioscapulohumeral Muscular Dystrophy Pipeline Assessment 2024: Therapies, Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular…
Facioscapulohumeral Muscular Dystrophy Market Outlook 2032 | Fulcrum Therapeutic …
In the year 2021, the total prevalent cases of FSHD were 78,790 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The Facioscapulohumeral Muscular Dystrophy therapeutics market is anticipated to grow in the coming years owing to the increasing prevalent population of FSHD patients in the 7MM, extensive research and development activities of pharmaceutical companies, along with the expected launch of emerging therapies in the market.
Several…
Facioscapulohumeral Muscular Dystrophy Pipeline Review | Latest FDA, EMA, and PM …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular…
